Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

p>In September 2006, Transition announced a global collaboration with Elan to develop and commercialize ELND-005/AZD-103.

In April 2007, Transition announced that the FDA granted Fast Track designation to the investigational drug candidate ELND-005/AZD-103 which is being developed in collaboration with Elan. Under the FDA Modernization Act of 1997, Fast Track designation is intended to facilitate the development and expedite the review of a drug or biologic if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs for such a condition.

On August 30, 2007, the Company announced the completion of Phase I Clinical Studies with ELND-005/AZD-103. Transition and its development partner Elan have performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic profile of ELND-005/AZD-103 in healthy volunteers. Approximately 110 subjects have been exposed to ELND-005/AZD-103 in multiple Phase I studies, including single and multiple ascending dosing; pharmacokinetic evaluation of levels in the brain; and CSF and plasma studies. ELND-005/AZD-103 was safe and well-tolerated at all doses and dosing regimens examined. There were no severe or serious adverse events observed. ELND-005/AZD-103 was also shown to be orally bio-available, cross the blood-brain barrier and achieve levels in the human brain and CSF that were shown to be effective in animal models for Alzheimer's disease. The next steps in the development of ELND-005/AZD-103 will be submission of data supporting Phase II studies to the FDA. Transition and Elan anticipate starting Phase II by the end of calendar 2007 or early 2008.

I.N.T.(TM) Technology for Diabetes

E1-I.N.T.(TM)

Transition's first Islet Neogenesis Therapy product, E1-I.N.T.(TM), a combination of Transition's epidermal growth factor analogue ("E1") and gastrin analogue ("G1"), has completed two Phase I clinical t
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 on ... courthouse was contained and extinguished by the city’s fire department before it caused major damage ... the time of the fire, and it was a fire alarm system that tipped off ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... ... 31, 2015 , ... Creating one of the most modern fertility centers in ... image that goes beyond the boundaries of fertility medicine. , As the leading ... with dependable patient support, affordable treatments, unending hope, and high fertility success rates — ...
(Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
(Date:7/31/2015)... Ohio (PRWEB) , ... July 31, 2015 , ... ... District Court for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) ... (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3
... (Nasdaq: IDIX ) announced today that management will ... Healthcare Conference on Tuesday, March 10th at 1:30 p.m. ET ... and Company 29th Annual Healthcare Conference on Tuesday , ... Boston Marriott Copley Place.The live and archived webcasts of the ...
... First sugar-free, functional water brand made specifically for kids ... YORK, March 3 WAT-AAH!, the first sugar-free, functional ... their mothers, announces the first official "WAT-AAH! Challenge" to ... juice over water. During the month of March, mothers ...
... and 14th year of consecutive product revenue growth. ... support growing non-US business.Q4 2008 Highlights:- Product revenues ... 161% to $4.7 million - Over 31,700 Masimo ... were shipped in Q4 2008- International realignment results ...
... has surprising impact on young people GAITHERSBURG, Md., March ... of breakfast for students, Sodexo, a leading provider of ... districts across the country, has created a list of ... National School Breakfast Week, March 2-6."Studies repeatedly show that ...
... taking Plavix, PPIs have 25 percent increased chance of ... Heart attack patients given the blood thinner Plavix, plus ... may be at increased risk of death or another ... are given Plavix (clopidogrel) to help reduce the risk ...
... lead to consumer confusionWASHINGTON, March 3 As ... in the diet, it,s important that people understand ... studies, according to the Corn Refiners Association (CRA). ... fructose and high fructose corn syrup, creates factually ...
Cached Medicine News:Health News:Let Water Be Water, LLC Introduces New 'WAT-AAH! Challenge' 2Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 11Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 12Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 13Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 14Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 15Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 16Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 2Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 3Health News:Pure Fructose Frequently Confused With High Fructose Corn Syrup 2
(Date:7/30/2015)... Calif. , July 30, 2015 IRIDEX ... will release its second quarter 2015 financial results after ...   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MISSISSAUGA, Ontario, June 22, 2011 CardioGenics Holdings ... magnetic beads business unit, which develops ultra sensitive ... its Canadian subsidiary, Luxspheres Inc. The beads business ... Company,s CardioGenics Inc. Canadian subsidiary ("CardioGenics"), will now ...
... N.J., June 22, 2011 ... Co. Ltd., and an international specialty pharmaceutical company, today ... Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment ... pain associated with chronic anal fissures.  Rectiv will be ...
Cached Medicine Technology:CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 2CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 3ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 2ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: